Application
Fig1: Western blot analysis of CD69 on different cell lysate using anti-CD69 antibody at 1/1,000 dilution. Positive control：Line1: JurkatLine2: L1210Line3: THP-1Application
Fig2: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-CD69 antibody. Counter stained with hematoxylin.Application
Fig3: Flow cytometric analysis of Hela cells with CD69 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).| Product Name | CD69 [E6-B6] |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | Activation inducer molecule (AIM/CD69) antibody Activation inducer molecule antibody AIM antibody BL-AC/P26 antibody BLAC/P26 antibody C-type lectin domain family 2 member C antibody CD69 antibody CD69 antigen (p60, early T-cell activation antigen) antibody CD69 antigen antibody CD69 molecule antibody CD69_HUMAN antibody CLEC2C antibody EA1 antibody Early activation antigen CD69 antibody Early lymphocyte activation antigen antibody Early T cell activation antigen p60 antibody Early T-cell activation antigen p60 antibody GP32/28 antibody Leu23 antibody Leukocyte surface antigen Leu-23 antibody MLR-3 antibody MLR3 antibody VEA antibody Very Early Activation Antigen antibody |
| Product description | CD69 is expressed as a disulfide-linked homodimer called the activation inducer molecule (AIM), which is composed of two differentially glycosylated forms of a single protein. CD69 is among the earliest antigens to appear after activation of T cells, B cells and NK cells. CD69 is expressed constitutively on platelets, CD4+ or CD8+ thymocytes, and germinal center T cells, but is absent from resting lymphocytes. |
| Immunogen | Recombinant protein |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG1 |
| Host Species | Mouse |
| Tested Applications | WBIHCFC |
| WB:1:250~1:1000 IHC:1:20~1:100 FC:1:100~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
|
| Species Reactivity | Human |
| Concentration | 2mg/ml |
| Alternative Names | Activation inducer molecule (AIM/CD69) antibody
Activation inducer molecule antibody
AIM antibody
BL-AC/P26 antibody
BLAC/P26 antibody
C-type lectin domain family 2 member C antibody
CD69 antibody
CD69 antigen (p60 early T-cell activation antigen) antibody CD69 antigen antibody CD69 molecule antibody CD69_HUMAN antibody CLEC2C antibody EA1 antibody Early activation antigen CD69 antibody Early lymphocyte activation antigen antibody Early T cell activation antigen p60 antibody Early T-cell activation antigen p60 antibody GP32/28 antibody Leu23 antibody Leukocyte surface antigen Leu-23 antibody MLR-3 antibody MLR3 antibody VEA antibody Very Early Activation Antigen antibody |
|---|---|
| Molecular Weight(MW) | 30 kDa |
| Cellular Localization | Membrane. |
| SwissProt ID | Q07108 |
|---|
Application
Fig1: Western blot analysis of CD69 on different cell lysate using anti-CD69 antibody at 1/1,000 dilution. Positive control：Line1: JurkatLine2: L1210Line3: THP-1
Application
Fig2: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-CD69 antibody. Counter stained with hematoxylin.
Application
Fig3: Flow cytometric analysis of Hela cells with CD69 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).| Positive Control | Jurkat, L1210, THP-1 cell lysate, human tonsil tissue, Jurkat. |
|---|---|
| Application Notes | WB:1:250~1:1000 IHC:1:20~1:100 FC:1:100~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, Preservative: 0.05% Sodium Azide. |
